Stock INTEG B INTEGRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Integrum AB

Equities

INTEG B

SE0009807266

Delayed Nasdaq Stockholm
Other stock markets
 03:37:22 2024-05-23 am EDT 		5-day change 1st Jan Change
53.4 SEK 0.00% Intraday chart for Integrum AB -2.20% +16.98%
May. 15 Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu CI
May. 02 Integrum Expands Its Product Offering to the United Kingdom Market CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1335 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INTEGRUM AB Stock Integrum AB
+16.98% 91.75M -
STRAUMANN HOLDING AG Stock Straumann Holding AG
-11.21% 20.97B
B
SONOVA HOLDING AG Stock Sonova Holding AG
+6.20% 19.01B
A
COCHLEAR LIMITED Stock Cochlear Limited
+7.82% 13.79B
B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-13.57% 2.16B -
EMBLA MEDICAL HF. Stock Embla Medical hf.
+6.01% 1.79B
B+
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+21.75% 1.5B
D-
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
+13.95% 616M -
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 411M - -
DELCATH SYSTEMS, INC. Stock Delcath Systems, Inc.
+88.70% 218M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. INTEG B Stock
  4. Ratings Integrum AB
Array ( [Edition] => en_US [UserType] => free [Content] => equities [codezb] => 61747291 )